Indivior Presents Data on SUBLOCADE Reducing OD Risk & Supporting Remission

Indivior Pharmaceuticals presented new scientific data at the ASAM Annual Conference, highlighting the effectiveness of its monthly injectable SUBLOCADE® for opioid use disorder (OUD). Studies showed SUBLOCADE significantly reduced the risk of non-fatal and fatal opioid overdoses compared to no treatment, with higher MOUD coverage leading to fewer overdose events. Provisional findings also indicated that OUD remission, defined by absence of DSM-5 symptoms, correlates with improved patient outcomes like lower craving and better quality of life. These findings reinforce the importance of sustained, evidence-based treatment and expand the body of evidence supporting SUBLOCADE's role in OUD recovery.